Subscribe to RSS
DOI: 10.1055/s-2006-948329
© Georg Thieme Verlag KG Stuttgart · New York
Obsessive-Compulsive Disorder Due to Neuroacanthocytosis Treated with Citalopram
A Case ReportPublication History
Publication Date:
30 August 2006 (online)
Neuroacanthocytois is a rare hereditary disease, which causes a degeneration of the striatum. Patients develop a choreatic movement disorder and also complex psychiatric symptoms, such as psychosis or Tourette's syndrome. We report a case of obsessive-compulsive disorder due to neuroacanthocytosis. The striatum plays an important role in the pathophysiology of obsessive-compulsive disorder. In Huntington's disease we also find obsessive-compulsive disorders, due to impairment of the fronto-striatal loop. Encouraged by similar pathophysiology and promising reports of selective serotonin reuptake inhibitors in this disease, we started a treatment with citalopram to which the patient responded very well.
References
- 1 Adams KH, Hansen ES, Pinborg LH, Hasselbalch SG, Svarer C, Holm S. et al . Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol. 2005; 8 391-401
- 2 American Psychiatric Association .Diagnostic and statistical manual of mental disorders. DSM-IV, 4th ed. Washington, DC; American Psychiatric Association 1994: 456-463
- 3 Baxter LR. Basal ganglia systems in ritualistic social displays: reptiles and humans; function and illness. Physiol Behav. 2003; 79 451-460
- 4 Bruneau MA, Lesperance P, Chouinard S. Schizophrenia-like presentation of neuroacanthocytosis. J Neuropsychiatry Clin Neurosci. 2003; 15 378-380
- 5 Cummings JL, Cunningham K. Obsessive-compulsive disorder in Huntington's disease. Biol Psychiatry. 1992; 31 263-270
- 6 De Marchi N, Daniele F, Ragone MA. Fluoxetine in the treatment of Huntington's disease. Psychopharmacology. 2001; 153 264-266
- 7 Fallon BA, Mathew SJ. Biological therapies for obsessive-compulsive disorder. J Psychiatr Pract. 2000; 6 113-128
- 8 Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL. et al . The Yale-Brown Obsessive Compulsive Scale. Arch Gen Psychiatry. 1989; 46 1006-1011
- 9 Hardie RJ, Pullon HW, Harding AE, Owen JS, Pires M, Daniels GL. et al . Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain. 1991; 114 13-49
- 10 Patzold T, Brune M. Obsessive compulsive disorder in Huntington disease: a case of isolated obsessions successfully treated with sertraline. Neuropsychiatry Neuropsychol Behav Neurol. 2002; 15 216-219
- 11 Pujol J, Soriano-Mas C, Alonso P, Cardoner N, Menchon JM, Deus J. et al . Mapping structural brain alterations in obsessive-compulsive disorder. Arch Gen Psychiatry. 2004; 61 720-730
- 12 Rossi S, Bartalini S, Ulivelli M, Mantovani A, Di Muro A, Goracci A. et al . Hypofunctioning of sensory gating mechanisms in patients with obsessive-compulsive disorder. Biol Psychiatry. 2005; 57 16-20
- 13 Saiki S, Hirose G, Sakai K, Matsunari I, Higashi K, Saiki M. et al . Chorea-acanthocytosis associated with Tourettism. Mov Disord. 2004; 19 833-836
- 14 Whiteside SP, Port JD, Abramowitz JS. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Res. 2004; 132 69-79
Correspondence
Benedikt HabermeyerMD
Department of Psychiatry·University of Basel
Wilhelm Klein-Strasse 27·4056 Basel
Phone: +41/61/325 55 60
Fax: +41/61/325 52 58
Email: benedikt.habermeyer@upkbs.ch